After biosimilars launch, reference biologics’ list price increases stop and net costs fall. Currently, 7 reference biologics have at least 1 biosimilar competitor on the market, creating direct competition for those drugs.
Most state Medicaid programs have predominantly transitioned the prescription drug benefit to the managed care setting, through which Medicaid managed care organizations (MCOs) and their contracted PBMs collaborate using their prescription drug management and broader care coordination and integration tools.
This paper provides a quantitative model consistent with the theory and evidence in which pharmacy benefit management on behalf of insurance plans serves these and other purposes in both monopoly and oligopoly provider settings. Calibrating the model to the U.S.
(Washington, D.C.) — As the Administration considers modifying price concessions for prescription drugs in Medicare and federal programs, the Pharmaceutical Care Management Association (PCMA) is releasing new data, “Reconsidering Drug Prices, Rebates, and PBMs,” showing drug manufacturers alone set prices –
The pharmacy benefit company market is competitive and diverse, with more than 70 full-service PBMs of varying size operating across the country. These companies differentiate themselves through the services, contract terms, and products they offer. Across this competitive industry is a common mission
Total US expenditures on pharmaceutical drugs…were $480 billion…Two-thirds of this total was captured by drug manufacturers in the form of net revenues.
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement today on the Congressional Budget Office’s (CBO) $43 billion score of point-of-sale rebates in Medicare Part D. CBO’s score is the latest in a series of official estimates
In case you missed it, former U.S. Senator Pat Toomey (R-PA) explains how the Biden Administration’s recent push targeting pharmacy benefit companies is a deflecting tactic that will only result in increased prescription drug costs in a recent op-ed published
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement today on the Administration’s new Blueprint on drug pricing: “We share the Administration’s goal of reducing drug prices. The key is to increase competition among drug companies so
As a reminder, the U.S. House of Representatives Committee on Oversight and Reform previously found, in a 2021 report, that PBM-negotiated rebates are not correlated with the list prices set by drug companies. The report also finds that “drug companies have
©2024 PCMA. All Rights Reserved.
